Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 1/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.56 |
| ▸ | LCLAT1 | Q6UWP7 | 9/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4762606 | 0.85 | STIM1 (0.56) | STIM1ORAI1LCLAT1KMT2AMEN1 | |
| SCHEMBL1826761 | 0.84 | STIM1 (0.64) | STIM1ORAI1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1825942 | 0.83 | KCNMA1 (0.64) | STIM1ORAI1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1828278 | 0.83 | ORAI1 (0.79) | STIM1ORAI1MAPTCYP2C9HTT | |
| SCHEMBL16363182 | 0.81 | STIM1 (0.61) | STIM1ORAI1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4762548 | 0.81 | STIM1 (0.56) | STIM1ORAI1KMT2AMEN1ALDH1A1 | |
| SCHEMBL4762823 | 0.76 | NPC1 (0.52) | STIM1ORAI1KMT2AMEN1ALDH1A1 | |
| SCHEMBL8257714 | 0.75 | IL2 (0.45) | LCLAT1MCL1 | |
| SCHEMBL4762642 | 0.74 | STIM1 (0.45) | STIM1ORAI1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8262166 | 0.74 | ORAI1 (0.52) | STIM1ORAI1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | claimed |
| EP-1846372-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1846372-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | claimed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | claimed |
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8592486-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| EP-1846372-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1846372-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | STIM1 2239/4885ORAI1 1677/4885LCLAT1 1054/4885 |
| US-20060173006-A1 | Compounds for inflammation and immune-related uses | CXCL8, CCR8, CXCR2 | STIM1 2239/4885ORAI1 1677/4885LCLAT1 1054/4885 |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | STIM1 2239/4885ORAI1 1677/4885LCLAT1 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.